Nuvalent Inc Cl A (NUVL) Stock Price, Quote & News

Company Profile

Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) wh...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 357 7000

Website: www.nuvalent.com

Address:

One Broadway, 14th Floor, Cambridge, United States

ISEEITALLTHETIME Oct. 4 at 5:53 PM

$NUVB Ask yourself why $NUVL's valuation is $7.5 billion, they don't even have a drug approved. Did you sell and now you are trying to get it cheaper?

0 · Reply

ISEEITALLTHETIME Oct. 4 at 3:53 PM

$NUVB It has been non stop selling at $NUVL for the last two years. It brings in to question their confidence in their company's future. $NUVB on the other hand, has seen virtually no insider selling, but lots of insider buys.

0 · Reply

Quantumup Sep. 30 at 1:58 PM

Jefferies🏁 $NUVB Buy/$10 $NUVL $BMY Jefferies said: Lead asset Ibtrozi has full FDA approval for ROS1+ NSCLC w/ a broad line-agnostic label -- multi-year treatment duration could drive significant revenue stacking vs what Street forecasts. Pipeline provides upside optionality w/ safusidenib (IDH1m glioma) set to advance into phase 3 and '1511 novel oral drug conjugate approach w/ clinical update in 2H. Cash $608M runway into 1H28 (our est). Initiate at Buy w/ PT $10.

0 · Reply

highnihilism Sep. 17 at 11:59 AM

IWM: Russell 2000 → $NUVL Nuvalent $MMS Maximus $TYRA Tyra Biosciences $PBH Prestige Consumer Healthcare $PEB Pebblebrook Hotel Trust

0 · Reply

highnihilism Sep. 16 at 3:11 PM

Biotech → $IRON Disc Medicine $ORIC Oric Pharmaceuticals $JANX Janux Therapeutics $NUVL Nuvalent $IMNM Immunome

0 · Reply

outlawinvestor1 Sep. 9 at 3:40 PM

$NUVB $NUVL

2 · Reply

JarvisFlow Sep. 8 at 1:11 PM

Wedbush updates rating for Nuvalent ( $NUVL ) to Outperform, target set at 115.

0 · Reply

Doozio Sep. 5 at 3:18 PM

$NUVL while da 🐑 in da HOOD get SKWD watching 🧠leader🐑 base.. out of the tightness the 🧠 spreads on the DLO 🐒🍌🧠⏰♾️

0 · Reply

IN0V8 Sep. 4 at 3:41 PM

$NUVL Opportunity Raymond James initiates coverage with outperform rating; PT $105

0 · Reply

Quantumup Aug. 20 at 3:56 PM

Piper Sandler (Aug. 18)🏁 $NUVL at an Overweight/$112. $RHHBY $PFE TAK NVS ABBV LLY JNJ $ZLAB $NUVB Piper Sandler said in its initiation report: Investors largely view $NUVL as a high quality precision oncology company but seem to be in a waiting pattern until we get closer to the 1L ALK data in a few years. We think the Street underestimates the near-term value creation over the next 18 months as we get (1) updated Ph II neladalkib data in 2L+ ALK NSCLC later this year which will confirm the degree of differentiation vs. lorlatinib, and by indirect comparison vs. alectinib, (2) initial commercial sales from zidesamtinib in 2026 in the ROS1 market which we think investors undervalue, and 3) potential initial data for NVL-330 in HER2+ NSCLC next year, in our view.

0 · Reply

Nuvalent, Inc. (NUVL) Presents at UBS Virtual Oncology Day Transcript

Sep 24, 2025, 6:30 AM EDT - 10 days ago

Nuvalent to Participate in the UBS 2025 Virtual Oncology Day

Sep 7, 2025, 4:45 AM EDT - 27 days ago

Nuvalent Presents Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025

Aug 28, 2025, 6:30 AM EDT - 5 weeks ago

Nuvalent to Participate in the Cantor Global Healthcare Conference 2025

Aug 13, 2025, 1:06 PM EDT - 7 weeks ago

Nuvalent to Present Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 Presidential Symposium

Aug 7, 2025, 6:30 AM EDT - 2 months ago

Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results

Jul 21, 2025, 6:30 AM EDT - 2 months ago

Nuvalent Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib for Patients with TKI-naïve ALK-positive NSCLC

Jun 24, 2025, 6:30 AM EDT - 3 months ago

Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC

Jun 23, 2025, 4:30 PM EDT - 3 months ago

Nuvalent Announces Timing of Pivotal Data for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC from ARROS-1 Clinical Trial of Zidesamtinib

Jun 18, 2025, 4:30 PM EDT - 3 months ago

Nuvalent Appoints Christy Oliger to Board of Directors

May 8, 2025, 7:31 AM EDT - 5 months ago

Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results

Apr 29, 2025, 1:09 PM EDT - 5 months ago

Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor

Apr 23, 2025, 10:28 AM EDT - 5 months ago

Nuvalent to Present Trial in Progress Posters for the ALKAZAR Trial of Neladalkib and HEROEX-1 Trial of NVL-330 at the 2025 American Society of Clinical Oncology Annual Meeting

Apr 1, 2025, 6:30 AM EDT - 6 months ago

Nuvalent to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

Mar 25, 2025, 5:24 PM EDT - 6 months ago

Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor, Neladalkib, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2025

Feb 28, 2025, 6:30 AM EST - 7 months ago

Nuvalent to Participate in Upcoming March Investor Conferences

Feb 27, 2025, 6:30 AM EST - 7 months ago

Nuvalent Outlines Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2024 Financial Results

Jan 13, 2025, 6:30 AM EST - 9 months ago

Nuvalent Details Strategy to Seek First Potential Approval in 2026 and Outlines Key Anticipated 2025 Milestones

Jan 10, 2025, 1:22 PM EST - 9 months ago

Nuvalent: A Logical Acquisition Target

Dec 19, 2024, 6:30 AM EST - 10 months ago

Nuvalent to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 9, 2024, 6:30 AM EST - 10 months ago

Nuvalent Appoints Grant Bogle to Board of Directors

Nov 26, 2024, 6:52 AM EST - 11 months ago

Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 12, 2024, 6:30 AM EST - 11 months ago

Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results

Sep 23, 2024, 12:34 PM EDT - 1 year ago

Nuvalent: Promising Data Keeps Validating Pipeline And Platform

Sep 18, 2024, 4:05 PM EDT - 1 year ago

Nuvalent Announces Closing of Upsized Public Offering of Common Stock

Sep 17, 2024, 1:20 PM EDT - 1 year ago

Nuvalent: NSCLC Program Now Lends Credibility Towards 2025 Pivotal Data Releases

Sep 16, 2024, 10:23 PM EDT - 1 year ago

Nuvalent Announces Pricing of Upsized Public Offering of Common Stock

Sep 16, 2024, 1:44 PM EDT - 1 year ago

Nuvalent Stock Jumps On ESMO Data Presentation, Seeks To Raise $350M Via Equity

Sep 16, 2024, 11:18 AM EDT - 1 year ago

Cancer Biotech Nuvalent's Stock Jumps on Positive Data

Sep 16, 2024, 7:00 AM EDT - 1 year ago

Nuvalent Announces Public Offering of Common Stock

Sep 14, 2024, 5:00 AM EDT - 1 year ago

Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines

Sep 13, 2024, 9:53 AM EDT - 1 year ago

Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655

Sep 9, 2024, 6:30 AM EDT - 1 year ago

Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class Profiles

Aug 29, 2024, 6:30 AM EDT - 1 year ago

Nuvalent to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 8, 2024, 6:30 AM EDT - 1 year ago

Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial Results

Jul 22, 2024, 6:30 AM EDT - 1 year ago

Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor

Jul 16, 2024, 6:30 AM EDT - 1 year ago

Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024

Jul 11, 2024, 6:30 AM EDT - 1 year ago

Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific Officer

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Nuvalent: Making Precise Progress In Its Oncology Pipeline

Jun 17, 2024, 12:19 PM EDT - 1 year ago

Nuvalent (NUVL) CEO On The Future Of Cancer Treatments

Jun 14, 2024, 7:15 AM EDT - 1 year ago

Nuvalent: NVL-655 Could Bring Blockbuster Potential

May 29, 2024, 6:30 AM EDT - 1 year ago

Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference

May 16, 2024, 4:01 PM EDT - 1 year ago

Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655

May 9, 2024, 6:30 AM EDT - 1 year ago

Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results

Apr 8, 2024, 4:30 PM EDT - 1 year ago

Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024

Mar 5, 2024, 4:52 PM EST - 1 year ago

Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024

Feb 27, 2024, 6:30 AM EST - 1 year ago

Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 27, 2024, 6:15 AM EST - 1 year ago

Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520

Feb 26, 2024, 2:55 PM EST - 1 year ago

Nuvalent: Pivotal NSCLC Programs Progressing With Additional Data In 2024

Feb 12, 2024, 6:30 AM EST - 1 year ago

Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid Tumors

ISEEITALLTHETIME Oct. 4 at 5:53 PM

$NUVB Ask yourself why $NUVL's valuation is $7.5 billion, they don't even have a drug approved. Did you sell and now you are trying to get it cheaper?

0 · Reply

ISEEITALLTHETIME Oct. 4 at 3:53 PM

0 · Reply

Quantumup Sep. 30 at 1:58 PM

0 · Reply

highnihilism Sep. 17 at 11:59 AM

IWM: Russell 2000 → $NUVL Nuvalent $MMS Maximus $TYRA Tyra Biosciences $PBH Prestige Consumer Healthcare $PEB Pebblebrook Hotel Trust

0 · Reply

highnihilism Sep. 16 at 3:11 PM

Biotech → $IRON Disc Medicine $ORIC Oric Pharmaceuticals $JANX Janux Therapeutics $NUVL Nuvalent $IMNM Immunome

0 · Reply

outlawinvestor1 Sep. 9 at 3:40 PM

$NUVB $NUVL

2 · Reply

JarvisFlow Sep. 8 at 1:11 PM

Wedbush updates rating for Nuvalent ( $NUVL ) to Outperform, target set at 115.

0 · Reply

Doozio Sep. 5 at 3:18 PM

$NUVL while da 🐑 in da HOOD get SKWD watching 🧠leader🐑 base.. out of the tightness the 🧠 spreads on the DLO 🐒🍌🧠⏰♾️

0 · Reply

IN0V8 Sep. 4 at 3:41 PM

$NUVL Opportunity Raymond James initiates coverage with outperform rating; PT $105

0 · Reply

Quantumup Aug. 20 at 3:56 PM

0 · Reply

JarvisFlow Aug. 19 at 12:00 PM

Piper Sandler updates rating for Nuvalent ( $NUVL ) to Overweight, target set at 112.

0 · Reply

justiceforb_85 Aug. 7 at 8:04 PM

$NUVL timeline a bit delayed for P3 but there's significant promise in this company.

1 · Reply

d_risk Aug. 7 at 2:22 PM

$NUVL - Nuvalent Inc. Class A Common Stock - 10Q - Updated Risk Factors NUVL’s 10-Q risk update highlights rising net losses ($184M H1 2025), Phase 3 trial delays, intensified regulatory, clinical, and commercial risks, expanded IP and third-party reliance concerns, evolving competitive and market challenges, plus new stock volatility and governance risks. #Biotechnology #MarketVolatility #IntellectualProperty #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/NUVL/10-Q/2025-08-07

0 · Reply

BearZoneBlitz Aug. 4 at 8:34 AM

$NUVL Nuclear energy play gaining attention. Breakout above $7.50.

0 · Reply

ISEEITALLTHETIME Aug. 1 at 1:49 PM

$XBI $NUVL The 10 year bond is down 11 ticks, this is very good for Biotechs. It means interest rates are going to be cut very soon.

0 · Reply

WallStVisions Jul. 25 at 8:51 AM

TGL - No dilution. No eyes. All setup. Launching AI this quarter + tapping into a multi-million user base. Trading at pennies with billion-dollar potential? This is where big trades are born before the herd. $BETS $NUVL $LUNR $AKAN

2 · Reply

BiotechBonesaw Jul. 9 at 12:23 AM

$NUVB because they’re busy taking on $PFE $NUVL and the other ROS1+ NSCLC competition!!!!!!!!!!!!!!!!! Or likely in discussions with someone that should buy them like $INCY or $GSK GLB 👍 ☘️ 🐂

0 · Reply

ISEEITALLTHETIME Jul. 1 at 12:00 AM

$NUVL $NUVB $PFE $BMY $RHHBY Here's a question, why aren't they saying this about Nuvation's drug, it's already been approved? This is what I have been saying all along, Nuvalents drug is superior to Nuvation's drug.

2 · Reply

Shagg85 Jun. 30 at 8:49 PM

$BMY $NUVB $NUVL $PFE $RHHBY pump on your Own ticker. they aren’t even close to release or FDA approval

0 · Reply

Quantumup Jun. 30 at 8:39 PM

Goldman Sachs assigned $NUVL at a Buy-$105 after its previous No Rating on their Initiation, plus⬆️its peak sales ests for nela/zide to ~$7B WW non-risk-adj'd, or ~$5B risk-adj'd in 2040. $NUVB $PFE $BMY $RHHBY Goldman Sachs said in its note:

0 · Reply

IN0V8 Jun. 25 at 11:28 PM

$NUVL Buy Leerink Partners raises target price to $140 from $125 H.C. Wainwright raises target price to $130 from $110

0 · Reply

The_Fact_ster Jun. 25 at 7:03 PM

$NUVL interesting. Data yesterday was good but valuation was already quite rich. Little delayed reaction?

0 · Reply

Market Cap	6.07B
Revenue (ttm)	0.00
Net Income (ttm)	-260.76M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	479,900
Avg Vol	455,974
Day's Range	N/A - N/A
Shares Out	72.11M
Stochastic %K	66%
Beta	1.30
Analysts	Strong Sell
Price Target	$116.38